Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Licenses Technology to Revivicor

NEW YORK, Oct. 11 (GenomeWeb News) - Benitec announced last week that it has non-exclusively licensed its DNA-directed RNA interference technology to Revivicor for use in regenerative medicine.


According to Benitec, Revivicor will use the technology to downregulate genes in transgenic pigs, creating tissue and organs that can be used for grafting and transplantation in humans.


Under the terms of the deal, Benitec received an upfront fee, and is due annual maintenance fees, a milestone payment upon US regulatory approval, and royalty payments. Additional terms were not disclosed.


The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.